Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00205166
First received: September 12, 2005
Last updated: October 25, 2012
Last verified: October 2012
  Purpose

We are studying the affect of caffeine on the sensitivity of detecting coronary artery disease (blockages in the blood flow to the heart) with adenosine tracer scans. Adenosine is a drug used routinely in patients to relax heart blood vessels in order to assess for the presence of coronary artery disease. Often, if patients have had caffeine, the adenosine scan is not used because of the belief that caffeine may reduce the ability to detect coronary artery disease. We would like to test whether caffeine affects our ability to detect coronary artery disease with adenosine tracer scanning. We will perform an imaging study of the heart with adenosine after you have received caffeine.


Condition Intervention
Coronary Artery Disease
Procedure: Cardiac SPECT imaging Rest and Stress
Drug: Caffeine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?

Resource links provided by NLM:


Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • This protocol has a specific aim of determining whether prior caffeine administration affects the sensitivity and specificity of adenosine perfusion scintigraphy for detection of impaired coronary vascular reserve. [ Time Frame: Assessment is made at the time of research adenosine perfusion scintigraphy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • determination of caffeine levels in patients instructed to hold caffeine prior to adenosine imaging [ Time Frame: Assess at time of lab sample results obtained ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: June 1999
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Caffeine 400 mg PO 1 hour before adenosine infusion
Procedure: Cardiac SPECT imaging Rest and Stress
adenosine perfusion scintigraphy
Drug: Caffeine
Caffeine 400 mg po
Active Comparator: 2
Caffeine 200 mg po one hour before adenosine infusion
Procedure: Cardiac SPECT imaging Rest and Stress
adenosine perfusion scintigraphy
Drug: Caffeine
Caffeine 200 mg po

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who have already completed rest/stress 99mTc sestamibi or 99mTc tetrofosmin imaging will be given a form describing this protocol and asked to volunteer for the additional scan

Exclusion Criteria:

  • history of asthma, bronchospastic COPD, or renal failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00205166

Locations
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Astellas Pharma US, Inc.
Investigators
Principal Investigator: Charles K Stone, MD Univeristy of Wisconsin
  More Information

No publications provided

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00205166     History of Changes
Other Study ID Numbers: 1999-109
Study First Received: September 12, 2005
Last Updated: October 25, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Wisconsin, Madison:
adenosine tracer scans
coronary artery disease
caffeine

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Caffeine
Adenosine
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Cardiovascular Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on September 22, 2014